SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
AbbVie Inc. (ABBV) trades at a trailing P/E of 88.9, forward P/E of 14.5. Trailing earnings yield is 1.12%, forward earnings yield 6.89%. PEG 0.03 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (38/100, Fail) — trailing P/E is well above the S&P 500 average of ~25, suggesting a premium valuation (P/E 88.9).
- Forward P/E 14.5 (down from trailing 88.9) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.03 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 1.12% — below bond yields — investors are paying a premium for expected growth rather than current earnings. Forward yield improves to 6.89% as earnings recover.
- Analyst consensus target $256.15 (+21.8% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 61/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
38/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — ABBV
Valuation Multiples
P/E (TTM)88.9
Forward P/E14.5
PEG Ratio0.03
Forward PEG0.03
P/B Ratio-114.89
P/S Ratio6.10
EV/EBITDA15.4
Per Share Data
EPS (TTM)$2.37
Forward EPS (Est.)$14.49
Book Value / Share$-1.81
Revenue / Share$34.35
FCF / Share$10.50
Yields & Fair Value
Earnings Yield1.12%
Forward Earnings Yield6.89%
Dividend Yield3.15%
SharesGrow IV$119.91 (-43%)
Analyst Target$256.15 (+21.8%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
17.1 |
1.07 |
21.91 |
3.96 |
3.66% |
| 2017 |
29.1 |
-3.12 |
30.28 |
5.47 |
2.66% |
| 2018 |
25.0 |
2.18 |
-16.82 |
4.34 |
3.93% |
| 2019 |
16.6 |
0.38 |
-16.05 |
3.94 |
4.85% |
| 2020 |
38.7 |
-0.80 |
13.66 |
3.90 |
4.32% |
| 2021 |
20.8 |
0.15 |
15.55 |
4.26 |
3.86% |
| 2022 |
24.2 |
9.22 |
16.59 |
4.93 |
3.51% |
| 2023 |
56.3 |
-0.96 |
26.45 |
5.04 |
3.85% |
| 2024 |
73.5 |
-6.08 |
94.54 |
5.58 |
3.51% |
| 2025 |
96.8 |
-116.18 |
-125.12 |
6.69 |
2.85% |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$3.63 |
$25.64B |
$5.95B |
23.2% |
| 2017 |
$3.30 |
$28.22B |
$5.31B |
18.8% |
| 2018 |
$3.68 |
$32.75B |
$5.69B |
17.4% |
| 2019 |
$5.28 |
$33.27B |
$7.88B |
23.7% |
| 2020 |
$2.72 |
$45.8B |
$4.62B |
10.1% |
| 2021 |
$6.45 |
$56.2B |
$11.54B |
20.5% |
| 2022 |
$6.63 |
$58.05B |
$11.84B |
20.4% |
| 2023 |
$2.72 |
$54.32B |
$4.86B |
9% |
| 2024 |
$2.39 |
$56.33B |
$4.28B |
7.6% |
| 2025 |
$2.36 |
$61.16B |
$4.23B |
6.9% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$14.57 |
$14.22 – $15.29 |
$67.15B |
$66.64B – $67.69B |
19 |
| 2027 |
$16.19 |
$15.20 – $17.48 |
$72.31B |
$70.33B – $73.61B |
18 |
| 2028 |
$17.87 |
$13.13 – $21.13 |
$77.59B |
$77.51B – $77.67B |
12 |
| 2029 |
$19.55 |
$19.08 – $19.89 |
$81.74B |
$80.23B – $82.84B |
10 |
| 2030 |
$20.05 |
$19.57 – $20.41 |
$83.44B |
$81.9B – $84.57B |
5 |
